HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon

Guy Francis Nzengui-Nzengui,Gaël Mourembou,Hervé M’boyis-Kamdem,Ayawa Claudine Kombila-Koumavor,Angélique Ndjoyi-Mbiguino
DOI: https://doi.org/10.1186/s12879-024-09156-9
IF: 3.7
2024-03-16
BMC Infectious Diseases
Abstract:In 2022, the WHO reported that 29.8 million people around the world were living with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25‌ 375 people in Gabon (54% of all those living with HIV in the country). The literature reports a frequency of therapeutic failure with first-line antiretrovirals (ARVs) of between 20% and 82%. Unfortunately, data relating to the failure of second-line ARVs are scarce in Gabon. This study aims to determine the profiles of HIV drug resistance mutations related to protease inhibitors in Gabon.
infectious diseases
What problem does this paper attempt to address?